Genetic Variant Ups Heart Failure Risk in Black Americans
May 14, 2024
-
2 min
7 Key Takeaways
-
1
V142I variant of transthyretin gene increases HF risk in Black Americans
-
2
Carriers face higher risk of HF hospitalization by age 63 and all-cause mortality by age 72
-
3
Estimated reduction in longevity ranges from
-
4
9 to
-
5
8 years
-
6
Early identification and treatment of V142I carriers with ATTRv-CA is crucial
-
7
Study published in JAMA reveals impact of the genetic variation on cardiovascular risks and public health
A recent study highlights the impact of the V142I variant of the transthyretin gene on heart failure (HF) and mortality in Black Americans. Carriers of this variant face a significantly higher risk of HF hospitalization by age 63 and all-cause mortality by age 72, contributing to approximately 1 million years of life lost among Black Americans aged 50 years and older. The findings underscore the importance of early identification and treatment of V142I carriers with ATTRv-CA to mitigate the significant public health impact.
Listen Tab content
